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Establishment of mixed chimerism through trans-
plantation of allogeneic donor bone marrow (BM)
into sufficiently conditioned recipients is an effec-
tive experimental approach for the induction of trans-
plantation tolerance. Clinical translation, however, is
impeded by the lack of feasible protocols devoid of
cytoreductive conditioning (i.e. irradiation and cyto-
toxic drugs/mAbs). The therapeutic application of reg-
ulatory T cells (Tregs) prolongs allograft survival in
experimental models, but appears insufficient to in-
duce robust tolerance on its own.We thus investigated
whether mixed chimerism and tolerance could be re-
alized without the need for cytoreductive treatment
by combining Treg therapy with BM transplantation
(BMT). Polyclonal recipient Tregs were cotransplanted
with a moderate dose of fully mismatched allogeneic
donor BM into recipients conditioned solely with
short-course costimulation blockade and rapamycin.
This combination treatment led to long-term multilin-
eage chimerism and donor-specific skin graft tolerance.
Chimeras also developed humoral and in vitro toler-
ance. Both deletional and nondeletional mechanisms
contributed to maintenance of tolerance. All tested
populations of polyclonal Tregs (FoxP3-transduced
Tregs, natural Tregs and TGF-b induced Tregs) were
effective in this setting. Thus, Treg therapy achieves
mixed chimerism and tolerance without cytoreduc-
tive recipient treatment, thereby eliminating a ma-
jor toxic element impeding clinical translation of this
approach.
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Introduction
Outcome after organ transplantation could be improved
through the establishment of donor-specific immunologi-
cal tolerance. Rodent models of tolerance through mixed
chimerism are among the most robust and are thus attrac-
tive candidates for clinical development (1–8). The excep-
tional clinical potential of the mixed chimerism approach
has recently been underscored by a pilot series of renal
transplant recipients cotransplanted with donor BM who
accepted their organ graft in most cases without mainte-
nance immunosuppression (9). Routine clinical application
of this approach, however, is prevented by the toxicity of
the cytoreductive recipient conditioning which is required
to allow even transient engraftment of MHC-mismatched
BM.
Since the concept’s introduction with myeloablative condi-
tioning (10), gradually less toxic murine mixed chimerism
regimens have been developed. However, the induction of
durable mixed chimerism in robust strain combinations has
universally required either recipient irradiation (2,3,6,11),
cytotoxic drug/antibody treatment (8,12,13) or clinically un-
obtainable high doses of BM (4,14,15). As irradiation and
cytotoxic drugs are associated with considerable medical
risks such as profound leukopenia (9), their elimination
from tolerance protocols is widely regarded as essential
for widespread clinical translation. This goal of a noncy-
toreductive mixed chimerism model with conventional BM
doses has remained elusive so far.
Tregs play a critical role in maintaining self-tolerance. The
therapeutic exploitation of Tregs has pronounced effects in
autoimmune (16), organ transplantation (17,18) and GVHD
models (19,20), but does not induce skin graft tolerance
across full MHC barriers on its own (11,17), which is re-
garded as a stringent test in rodent models. Numerous
naturally occurring and experimentally designed subsets of
Tregs have been described that are being considered for
751
Pilat et al.
clinical application (21). Through transduction with FoxP3,
large numbers of Tregs (denoted here FoxP3-Tregs), whose
properties resemble those of natural Tregs, can be gener-
ated for experimental purposes (22,23). Although the role
of FoxP3 in humans is more complex (24), lentiviral trans-
duction of FoxP3 has recently allowed generation of stable
human Tregs (23). Induction of Tregs through in vitro ex-
posure of murine T cells to TGF-b (iTregs) likewise allows
the production of large quantities of Tregs (25,26). Natu-
ral CD4+CD25+ Tregs (nTregs) are currently already under
evaluation in several clinical trials (27).
We therefore investigated the therapeutic potential of sev-
eral populations of Tregs (FoxP3-Tregs, nTregs and iTregs)
to induce engraftment of conventional doses of allogeneic
BM, mixed chimerism and transplantation tolerance with-
out cytoreductive recipient conditioning.
Materials and Methods
Animals
Female C57BL/6 (B6, recipient, H-2b), Balb/c (donor, H-2d) and C3H/N (third
party, H-2k) mice were purchased from Charles River Laboratories (Sulzfeld,
Germany). This donor-recipient strain combination is one of the most strin-
gent models as it crosses MHC mismatches plus minor histocompatibil-
ity antigen mismatches, and as B6 recipients are relatively costimulation
blockade-resistant (13,28). All mice were housed under specific pathogen-
free conditions and were used at 6 to 12 weeks of age. All experiments
were approved by the local review board of the Medical University of Vi-
enna, and were performed in accordance with national and international
guidelines of laboratory animal care.
Generation of tregs
For FoxP3-Tregs, vector pCMMP-FoxP3-IRESeGFP (FoxP3/GFP) or control
vector pCMMP-IRESeGFP (GFP), vector pMD containing viral proteins gag
and pol and packaging vector pMD.G encoding for VSV-G protein (16) or
K73 encoding for an ecotrophic envelope (kindly provided by Dr. Christo-
pher Baum, Hannover Medical School, Germany) were transfected into 293
T cells, retroviral supernatant was recovered, concentrated by ultracentrifu-
gation and viral titer was determined. For retroviral infection CD4+ cells
were isolated from B6 spleen and lymph nodes by magnetic bead sort-
ing (L3T4 microbeads; Miltenyi Biotec, Bergisch Gladbach, Germany), and
were cultured in plates coated with 10 lg/mL anti-CD3 (145–2C11), 1 lg/mL
anti-CD28 (37.51) (BD Pharmingen, San Jose, CA) and in the presence of
100 U/mL rmIL-2 (Sigma-Aldrich, St. Louis, MO). Cells were infected twice
(d2 and 3) with high-titer VSV-G pseudotyped retrovirus at a multiplicity of
infection of 5–10 as described previously (16). Cells were FACS sorted for
GFP expression on d4. We achieved transduction efficiencies of up to 48%.
The vector contained FoxP3 followed by an internal ribosomal entry site
for bicistronic GFP expression. In some experiments, an ecotrophic enve-
lope instead of VSV-G protein was used, resulting in higher transduction
efficiencies.
nTregs were isolated from spleen and lymph nodes of naı¨ve B6 mice.
CD4+CD25+ cells were purified by magnetic bead separation using nega-
tive selection for CD4+ and subsequent positive selection of CD25+ by incu-
bation with PE-conjugated anti-CD25 (7D4) followed by anti-PE microbeads
(CD4+CD25+ Regulatory T-cell Isolation Kit; Miltenyi Biotec). Purity of sepa-
rated cells was >90%. Cells were used in vivo after cultivation for 5 days in
plates coated with 10 lg/mL anti-CD3 (145–2C11) and 1 lg/mL anti-CD28
(37.51) (BD Pharmingen) in the presence of 100 U/mL IL-2 (Sigma).
For generation of iTregs, CD4+ cells were isolated from B6 spleen and
lymph nodes by magnetic bead sorting (L3T4 microbeads; Miltenyi Biotec),
and were cultured for 5 days in plates coated with 10 lg/mL anti-CD3 (145–
2C11), 1 lg/mL anti-CD28 (37.51) (BD Pharmingen) in the presence of 100
U/mL IL-2 (Sigma) and 5 ng/mL rhTGFbeta (R&D Systems, Minneapolis,
MN) (26). All Treg populations were phenotypically characterized by flow
cytometry before in vivo use.
Suppression assay and mixed lymphocyte reaction (MLR)
The 4 × 105 B6 responder cells (unseparated splenocytes) were cocultured
with escalating numbers of FoxP3-transduced Tregs (2 × 105, 4 × 105, 8 ×
105, for a ratio of 2:1, 1:1, 1:2, respectively) or freshly sorted CD4+CD25high
Tregs respectively, in the presence of 4 × 105 irradiated (30 Gy) Balb/c
stimulator cells (unseparated splenocytes). Cells were pulsed with [3H]-
thymidine (Amersham, Biosciences, UK) for 18 h after 72 h of incubation.
Incorporated radioactivity was measured using scintillation fluid in a ß-
counter. Stimulation indices (SI) were calculated in relation to medium con-
trols. MLRs were performed with unseparated splenocytes as described
previously (4).
BMT protocol
Groups of age-matched B6 recipients received costimulation blockade con-
sisting of anti-CD40L (CD154) mAb (MR1, 1 mg, d0) and CTLA4Ig (0.5 mg,
d2) (3), a short course of rapamycin (0.1 mg/mouse, d-1, d0 and d2) (Alexis
Biochemicals, San Diego, CA) (6) and approximately 2 × 107 unseparated
BM cells recovered from Balb/c donors (d0, i.v.) with or without additional
Treg treatment. Treg treatment consisted of 4 × 106 FoxP3-Tregs (d0) or
3 × 106 nTregs (d0) or 5 × 106 iTregs (d0). Anti-CD154 mAb was purchased
from BioXCell (West Lebanon, NH), hCTLA4Ig (abatacept) was generously
provided by Bristol-Myers, Squibb Pharmaceuticals (Princeton, NJ).
Secondary BMT
Eight weeks after BMT, BM cells were recovered from primary recipients
and transplanted into secondary B6 mice conditioned with 10 Gy total
body irradiation (TBI), depleting doses of anti-CD8 (2.43; 0.5 mg/mouse)
and anti-CD4 (GK1.5; 0.5 mg/mouse) mAbs and anti-CD40L mAb (MR1;
0.5 mg/mouse) to promote engraftment. On the day of reconstitution each
secondary recipient was transplanted with 5 × 107 BM cells recovered
from one chimera (i.v.).
Antidonor antibodies
Recipient serum recovered 1 week, 2 weeks and>3 months post-BMT was
heat-inactivated and incubated with recipient- and donor-type thymocytes
(which are low in Fc-receptors, reducing background). Binding of serum IgG
Abs to thymocytes was analyzed by flow cytometry using FITC-conjugated
rat anti-mouse IgG1 and IgG2a/2b (BD Pharmingen).
Flow cytometric analysis of Treg phenotype, chimerism
and deletion
Multicolor flow cytometric analysis of Treg phenotype, multilineage
chimerism and Vb-subunit expression was performed as described pre-
viously (3). Chimerism was calculated as the net percentage of donor
MHC class I+ (H-2Dd, 34-2-12) cells among leukocyte lineages, as de-
scribed previously (3,6). Mice were considered chimeric if donor cells
were detectable by flow cytometry within both the myeloid lineage
and at least one lymphoid lineage. For analysis and sorting of Tregs,
mAbs with specificity against CD4 (RM4-4), CD25 (7D4) and CD62L
(L-selectin, Mel-14) were used. For intracellular staining, a FoxP3 (FJK-
16s) staining Kit (eBioscience, San Diego, CA) was used according
to the manufacture’s protocol. Cell sorting was performed on a FACS
Aria (BD Biosciences, San Jose, CA), purity of sorted populations was
>95%.
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Histological analysis
Four micrometers sections were cut from paraffin-embedded tissue fixed
in 4.5% formalin (with a buffered pH of 7.5), stained with hematoxilin-
eosin and Giemsa according to standard protocols, and analyzed by an
experienced pathologist. Mast cells were counted in five high-power fields
(HPF, magnification 400×), and mean density per HPF was calculated. For
immuno-histochemistry, 6 lm sections were prepared and biotinylated anti-
Foxp3 (clone FJK-16S, eBioscience) followed by Streptavidin/HRP (Dako,
Glostrup, Denmark) was used.
Isolation of genomic DNA and PCR
DNA was isolated from skin grafts, lymph nodes, BM, spleen, thy-
mus and FoxP3-transduced cells using the DNeasy Blood & Tis-
sue kit (Qiagen, Hilden, Germany). GFP product was amplified
using primer 5′-CGCACCATCTTCTTCAAGGACGAC-3′ and primer 5′-
AACTCCAGCAGGACCATGTGATCG-3′. FoxP3 transduced NIH3T3 cells and
retroviral vector were used as positive controls, b-actin DNA was amplified
as an internal control (16).
Results
Phenotypic and functional characteristics
of FoxP3-Tregs, nTregs and iTregs
Three different populations of polyclonal recipient-type
Tregs were generated for in vivo use. Polyclonal FoxP3-
Tregs were produced by retroviral transduction of wild-type
B6 CD4+ lymphocytes with a retroviral vector containing
FoxP3 followed by an internal ribosomal entry site (IRES)
for direct GFP translation (16). CD4+CD25+ nTregs were
separated from B6 spleen and lymph nodes and trans-
ferred in vivo upon polyclonal in vitro activation. For gener-
ation of iTregs, B6 CD4+ cells were cultured in vitro in the
presence of TGF-b and IL-2 (26). All three cell populations
showed a phenotypic pattern characteristic of Tregs, includ-
ing expression of high levels of FoxP3, CD25 and CD62L
(Figure 1A–C). Little is known about the ability of poly-
clonal FoxP3-Tregs to suppress alloreactivity across MHC
barriers, in particular as they were ineffective in a minor-
mismatch-only heart transplant model (29). We thus first
assessed their regulatory function in vitro. Coculture as-
says revealed that FoxP3-Tregs suppressed proliferation of
T cells in response to alloantigen in a dose-dependent man-
ner (Figure 1D) (similar results were obtained for iTregs;
data not shown).
Treg treatment leads to mixed chimerism without
cytoreductive recipient conditioning
Next, the three Treg populations were used in vivo as
part of a BMT regimen. Without any irradiation or cyto-
toxic drug/antibody conditioning, B6 mice received a con-
ventional dose of fully mismatched Balb/c BM (2 × 107
cells per mouse) under the cover of costimulation block-
ade (CTLA4Ig, anti-CD40L mAb) and a brief course of ra-
pamycin. Rapamycin was used as it has an engraftment-
enhancing effect (which, however, is insufficient for
engraftment of such a BM dose without recipient irra-
diation, as shown by the results of the control groups
depicted in Figure 2A–C) (6) and positively affects Treg
function in vitro and in vivo (30–32). Treg treatment (3 ×
106 to 5 × 106 cells/recipient) led to long-term mixed
chimerism in the vast majority of BMT recipients whereas
no BMT recipient developed chimerism without Treg treat-
ment (6/7 long-term chimeras [plus one transient chimera]
with FoxP3-Tregs; 3/4 chimeras with nTregs, 5/6 chimeras
with iTregs; 0/13 chimeras without Tregs; at 3–7 months
post-BMT; p = 0.0002 for FoxP3-Tregs; p = 0.0059 for
nTregs; p = 0.0005 for iTregs; Fisher’s exact test; in-
dependent repeat experiments performed for iTreg and
nTreg treatment showed similar results). BMT recipients
treated with Tregs reached substantial levels of macro-
chimerism (mean blood chimerism levels ∼3 months
post-BMT among the myeloid lineage were 5–10%)
(Figure 2A–C). Rapamycin was indispensable as adjunc-
tive treatment given together with Tregs, as mice receiv-
ing Tregs without rapamycin uniformly failed to develop
chimerism (8/8 chimeras with rapamycin; 0/8 without ra-
pamycin; p = 0.0002, Fisher’s exact test; 2 weeks post-
BMT) (Figure 2D). Thus, the combination of Tregs with
rapamycin—but not either alone—allowed BM engraft-
ment without cytoreduction.
Chimerism in Treg-treated BMT recipients was of mul-
tilineage nature, with donor populations present in all
tested leukocyte lineages, including CD4 and CD8 cells
(Figure 3A–C). Chimerism levels in peripheral blood corre-
lated with chimerism in lymphoid organs (BM and spleen,
data not shown). Multilineage chimerism persisted for the
length of follow up (>5 months post-BMT), suggesting
that donor hematopoietic stem cells had successfully en-
grafted and survived in recipient mice (33). To assess more
directly whether hematopoietic stem cells had success-
fully engrafted, BM recovered from iTreg-treated chimeras
8 weeks post-BMT was transplanted into myeloablated
secondary B6 recipients (n = 3). Long-term multilineage
donor chimerism was detectable in 2/3 secondary re-
cipients (15.3% mean CD4 chimerism, 5.8% mean CD8
chimerism, 2.4% mean B-cell chimerism, 6.0% mean
myeloid chimerism; 12 weeks postsecondary BMT), sug-
gesting that donor hematopoietic stem cells had indeed
successfully engrafted and survived in the primary re-
cipients (Figure 3D). Thus, allogeneic stem cell engraft-
ment and long-lasting multilineage chimerism was induced
through Treg therapy without cytoreductive recipient con-
ditioning.
Chimeras induced through Treg treatment
demonstrate skin graft tolerance
Donor skin graft survival is commonly regarded as a
stringent test for assessing transplantation tolerance. We
therefore grafted BMT recipients with donor and third party
skin (4–6 weeks post-BMT). Most mice treated with Tregs,
but no mouse without Tregs, accepted donor skin for the
length of follow-up, and all mice promptly rejected third
party grafts (7/7 donor skin graft acceptors with FoxP3-
Tregs; 3/4 with nTregs, 5/6 with iTregs vs. 0/13 without
Tregs, p < 0.01 for each Treg group, Fisher’s exact test;
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Figure 1: Phenotypical and func-
tional characterization of FoxP3-
Tregs, nTregs and iTregs. B6 CD4+
cells were transduced with FoxP3/GFP
virus and sorted for GFP expres-
sion to generate FoxP3-Tregs (A) or
in vitro cultured with TGFb to yield
iTregs (C). B6 CD4+CD25+ nTregs (B)
were isolated from spleen and lymph
nodes and activated in vitro. Prior to
in vivo transfer, cells were phenotypi-
cally characterized by flow cytometry.
All three populations expressed high
levels of FoxP3, CD25 and CD62L. Typ-
ical histograms (gated on CD4+ cells)
for intracellular expression of FoxP3
and surface expression of CD25 and
CD62L are shown. (D) FoxP3-Tregs
suppressed proliferation of B6 spleno-
cytes in response to allogeneic stimula-
tion (Balb/c splenocytes) (as do freshly
sorted control CD4+CD25+ Tregs),
whereas coculture with CD4+CD25−
sorted cells resulted in enhanced prolif-
eration. SI (stimulation index) was cal-
culated by dividing the mean cpm from
responses against syngeneic (B6) or
allogeneic (Balb/c) stimulator cells by
mean background cpm.
MST [median survival time] >100 days for donor grafts
of each Treg group; MST = 14 without Tregs; third-party
C3H skin grafts were rejected within 15 days in all groups)
(Figure 4A–C). The same regimen without BM (iTregs, cos-
timulation blockade and rapamycin) failed to induce skin
graft tolerance (n = 6; MST = 20 days; not shown). Hence,
combining Treg treatment with BMT leads to donor-specific
skin graft tolerance.
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Figure 2: Treg treatment together with rapamycin induces mixed chimerism without cytoreductive conditioning. Groups of B6
mice were grafted with 2 × 107 Balb/c BM cells under the cover of costimulation blockade (anti-CD154, CTLA4Ig) and rapamycin and
were additionally treated (A) with ( , 4 × 106, n = 7) or without (♦, n = 6) recipient-derived FoxP3-Tregs, (B) with ( , 3 × 106, n = 4) or
without (♦, n = 7) recipient-derived nTregs or (C) with ( , 5 × 106, n = 6) or without (♦, n = 7) recipient-derived iTregs, respectively. Only
recipients treated with any of the Treg populations developed chimerism. Donor (H-2Dd+) chimerism among leukocytes of the myeloid
(Mac1+) lineage was assessed by flow cytometry of peripheral blood at multiple time points and is shown as mean percent (error bars
indicate standard deviation; nTreg and iTreg groups were done in the same experiment, therefore the control group is shown twice in
B + C). Repeat experiments performed with nTregs and iTregs showed similar results. ∗∗p < 0.005, ∗p < 0.05 with versus without Tregs
(two-sided Student’s t-test). (D) B6 mice received 2 × 107 Balb/c BM cells under the cover of costimulation blockade and 5 × 106 iTregs
with or without rapamycin. Recipients treated without rapamycin failed to develop chimerism (• iTregs with rapamycin n = 8; iTregs
without rapamycin, n = 8; p = 0.0002, Fisher’s exact test). Donor (H-2Dd+) chimerism among leukocytes of the myeloid (Mac1+) lineage
is shown 2 weeks post-BMT as scatter plot (mean and standard deviation are indicated).
Chimeras induced through Treg treatment show
humoral and in vitro tolerance
Development of antidonor Abs (antibodies) is associ-
ated with the occurrence of chronic rejection and late
graft loss in clinical transplantation and suggests incom-
plete tolerance in the experimental setting (34). Hence
we tested BMT recipients for the presence of anti-
donor antibodies early (1 and 2 weeks) and late (>3
months) after BMT through flow cytometric assessment
of recipient serum binding to donor cells. No antidonor
Abs were detectable in chimeras treated with Tregs
at any time point, whereas control mice (BMT recipi-
ents receiving the same regimen without Tregs) devel-
oped substantial levels of antidonor Abs at late time
points (data not shown). Thus, Treg-treatment prevents
development of a humoral antidonor response in BMT
recipients.
To further characterize the state of tolerance, in vitro MLR
assays were performed. Hyporesponsiveness toward the
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Figure 3: Treg treatment leads to multilineage chimerism and stem cell engraftment. Chimerism in Treg-treated mice was of
multilineage nature as shown by the presence of donor cells among the T-cell (CD4, CD8), B-cell (B220) and myeloid (Mac1) lineages.
Two-color flow cytometry plots are shown from representative BMT recipients ∼3 months post-BMT treated with (A) FoxP3-Tregs, (B)
nTregs and (C) iTregs. (D) BM was recovered from iTreg-treated chimeras (8 weeks post-BMT; n = 3) and transplanted into myoablated
secondary B6 recipients. Donor chimerism was detectable in the T-cell (CD4, CD8), B-cell (B220) and myeloid (Mac1) lineages 12 weeks
postsecondary BMT, indicating that donor hematopoietic stem cells had engrafted in primary recipients. Flow cytometry plots are shown
from one secondary recipient. Numbers indicate the net percentage of donor chimerism in the depicted lineage (for calculation algorithm,
please see section ‘Materials and Methods’).
donor was observed already 1 week post-BMT in Treg-
treated recipients (Figure 4D) and was reduced to the level
of self-reactivity during long-term follow-up (Figure 4E).
Thus, Treg-treated chimeras demonstrate in vivo and in
vitro tolerance.
Intra-graft frequencies of mast cells and Tregs are
increased in Treg-treated chimeras
In the Treg groups, donor skin grafts remained macroscop-
ically intact for the length of follow up. Histopathological
analysis at the end of the observation period showed an
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Figure 4: Chimeras induced through Treg treatment develop donor-specific skin graft tolerance and hyporesponsiveness in vitro.
Donor-specific tolerance was assessed by grafting of full thickness donor and third party (C3H) tail skin 4–6 weeks post-BMT. Grafts were
considered to be rejected when less than 10% remained viable. Donor skin graft survival was significantly prolonged in BMT recipients
treated with (A) FoxP3-Tregs (, n = 7; p = 0.0002) compared to BMT recipients without Tregs (, n = 6); and in recipients treated with
(B) nTregs (, n = 4; p = 0.0360) and (C) iTregs (, n = 6; p = 0.0043) compared to the controls without Tregs (, n = 7, same control
group for B + C). Third-party grafts were promptly rejected in all groups (Treg-treated •, control ). Survival was calculated according
to the Kaplan–Meier product limit method and compared between groups using the log-rank test. Repeat experiments performed with
nTregs and iTregs showed similar results. (D,E) Mixed lymphocyte reaction results from selected BMT recipients were obtained early (1
week post-BMT) and at the end of follow-up (22 weeks post-BMT). (D) Early MLRs (1 week post-BMT) demonstrate hyporesponsiveness
toward the donor in Treg-treated recipients (n = 2) in comparison to controls without Tregs (p = 0.0120, SI antidonor compared to
controls). (E) Long-term chimeras of Treg-treated mice (nTreg, n = 2; iTreg, n = 3) showed specific hyporesponsiveness toward the donor
in vitro (p = 0.0446 for nTregs; p = 0.0063 for iTregs, SI antidonor compared to naı¨ve B6 mice). SIs were calculated by dividing the mean
cpm from responses against recipient (black column; B6), donor (white column; Balb/c), or third-party (gray column; C3H) stimulator cells
by mean background cpm (i.e. cpm with no stimulator population). Error bars indicate standard deviation.
intact epidermis without lymphocytic infiltrates, intact skin
adnexa and weak-to-moderate lymphocytic infiltrates in
the dermis. Donor grafts of Treg-treated chimeras were
remarkable for an abundance of mast cells, which have
been linked to Treg-mediated tolerance (35). The frequency
of graft-infiltrating mast cells was significantly increased
in Treg-treated mice over tolerant chimeras induced with
a nonmyeloablative regimen in which maintenance of
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Figure 5: Donor skin grafts of Treg-
treated chimeras showhigh frequen-
cies of mast cells and Tregs. (A)
Histopathology of donor skin grafts
from Treg-treated chimeras revealed
high frequencies of mast cells (Giemsa)
and FoxP3 positive cells (immunohisto-
chemistry) (HE, hematoxylin and eosin
stain, magnification 100×; FoxP3,
immunohistochemistry with specific
FoxP3 antibody, magnification 400×;
Giemsa, Giemsa staining, magnifica-
tion 200×; representative graft shown
5 months post-BMT). (B) Genomic
DNA isolated from skin grafts of FoxP3-
Treg treated mice (n = 3) was sub-
jected to PCR analysis specific for GFP.
Grafts lacked detectable GFP expres-
sion, indicating that graft-infiltrating
FoxP3 Tregs did not originate from
the therapeutically administered Tregs.
FoxP3-transduced NIH3T3 cells and
FoxP3 vector were used as positive
controls. DNA levels of GFP (upper
panel) and b-actin (lower panel) are
shown.
tolerance does not depend on regulation (36) (mean den-
sity of mast cells [5 HPF counted] 28.6, n = 7, vs. 17.9,
n = 3 controls, p = 0.0467; Student’s t-test) (Figure 5A).
As immunohistochemistry also revealed substantial num-
bers of FoxP3 positive cells within donor grafts (37) (Figure
5A), the question arose as to whether the graft-infiltrating
FoxP3+ cells originate from the therapeutically adminis-
tered Tregs. To address this question directly, we ana-
lyzed DNA isolated from donor skin grafts from FoxP3-Treg
treated mice for GFP expression by PCR. No GFP expres-
sion was detectable in the skin grafts, indicating that the
FoxP3 positive Tregs infiltrating the donor grafts did not de-
scend from the Tregs therapeutically applied at the time of
BMT (Figure 5B). Already 2 weeks after BMT (earliest time
point analyzed), no GFP+ cells were detectable by flow
cytometry in peripheral blood in FoxP3-Treg treated mice,
hinting that FoxP3-Tregs did not persist/circulate in large
quantities. PCR analysis at the end of follow up (>5 months
post-BMT) showed absence of GFP+ cells also in lym-
phoid organs (bone marrow [BM], spleen, lymph nodes,
thymus; not shown), indicating a limited life-span for trans-
ferred Tregs. Taken together, these data suggest that toler-
ance induced through Treg therapy with noncytoreductive
BMT is associated with the presence of graft-infiltrating
mast cells and of Tregs not originating from the transferred
population.
Chimeras induced through Treg treatment
demonstrate partial central and peripheral deletion
of donor-reactive T cells
Depending on the specifics of the chimerism model,
both deletional (central and peripheral) and nondele-
tional mechanisms contribute to tolerance to varying
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Figure 6: Chimeras induced through Treg treatment demon-
strate partial central and peripheral deletion of donor-reactive
T cells late after BMT. (A) Percentages of Vb11+ and Vb5+ (but
not Vb8+) CD4+ splenocytes (SPL) were significantly reduced in
Treg-treated mice (red bars, n = 7) in comparison to naı¨ve B6 mice
(gray bars, n = 5; p = 0.0003 for Vb11+, p = 0.0309 for Vb5+)
and in comparison to BMT recipients without Tregs (black bars,
n = 6; p = 0.0026 for Vb11+, p = 0.0128 for Vb5+; 25 weeks
after BMT). (B) CD8+ splenocytes (SPL) were also significantly
degrees (7,36,38). In chimeras, the frequency of certain
superantigen-reactive T-cell populations correlates with the
deletion of ‘truly alloreactive’, donor-specific CD4 cells (as
it can be assessed directly by employing TCR-transgenic
T cells recognizing donor MHC [39]) and hence is a use-
ful surrogate marker to measure whether deletion occurs
(3,4). T cells expressing particular Vb subunits (i.e. Vb11+
and Vb5+ in the strain combination used herein) recog-
nize endogenous superantigen bound to the donor MHC
class II allele I-E (40,41), which is not expressed in the
recipient strain B6. No deletion was detected immediately
after BMT in peripheral blood, spleen or thymus (∼2 weeks
post-BMT in peripheral blood, 1 and 2 weeks post-BMT in
spleen and thymus, not shown). However, we observed a
significant deletion of CD4 cells in peripheral blood (data
not shown) and spleen in Treg-treated BMT recipients late
after BMT (25 weeks post-BMT) (Figure 6A). No such
deletion was seen in control mice without Tregs. Dele-
tion late after BMT was significant, but was not complete
(compared to naı¨ve Balb/c). CD8 splenocytes were also
clonally deleted, providing evidence for intrathymic dele-
tion taking place because mature superantigen-reactive
CD8 cells—in contrast to CD4 cells—are not deleted
extrathymically (as they do not efficiently bind to the
superantigen-presenting MHC II), but only intrathymically
at the double positive stage of development (Figure 6B).
Central deletion was also directly evident among thymo-
cytes of Treg-treated long-term chimeras (22 weeks post-
BMT) (Figure 6C). The degree of deletion of CD4 spleno-
cytes was more profound than that of CD8 splenocytes
(54% vs. 27% deletion of Vb11, p = 0.0028). This differ-
ence in the extent of deletion between CD4 and CD8—
with CD4s being deleted significantly more extensively—
suggests that peripheral deletion of CD4 cells also took
place, in addition to central deletion occurring for both
CD4 and CD8. Thus, intra- and extrathymic clonal deletion
was evident in chimeras, but was not complete, revealing
that both deletional and nondeletional mechanisms con-
tribute to maintenance of tolerance in Treg-induced mixed
chimeras.
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
deleted in Treg-treated chimeras in comparison to naı¨ve B6 con-
trols, indirectly indicating central deletion (as mature superantigen-
reactive CD8 cells are not deleted extrathymically) (p = 0.0002 for
Vb11+, p = 0.0141 for Vb5+). (C) Percentages of Vb11+ and Vb5+
(but not Vb8+) single-positive CD4+ thymocytes (THY) were sig-
nificantly reduced in Treg-treated chimeras (red bars, n = 3) in
comparison to naı¨ve B6 mice (gray bars, n = 3; p = 0.0330 for
Vb11+, p = 0.0187 for Vb5+) and in comparison to BMT recip-
ients without Tregs (black bars, n = 7; p = 0.0102 for Vb11+,
p = 0.0151 for Vb5+; 22 weeks after BMT). Deletion was as-
sessed by multicolor flow cytometry in selected mice. Gray bars
denote naı¨ve B6 controls, white bars denote naı¨ve Balb/c controls.
p values are shown for comparison between groups (two-sided
Student’s t-test), error bars indicate standard deviation.
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Discussion
The presented studies show that polyclonal recipient
Tregs induce engraftment of conventional doses of allo-
geneic BM in recipients conditioned solely with costimu-
lation blockers and rapamycin, leading to long-term mixed
chimerism and donor-specific in vivo and in vitro tolerance.
This unique protocol avoids all cytotoxic recipient treat-
ment (irradiation, cytotoxic Abs and drugs).
The mixed chimerism approach resembles a two-edged
sword. Its unparalleled effectiveness in achieving robust
tolerance is counterbalanced by the toxicity of the dras-
tic cytoreductive recipient preparation necessary for BM
engraftment. Our results provide proof-of-concept that
mixed chimerism and tolerance can be attained without
toxic recipient preparation. Two of the remaining com-
ponents of our regimen—rapamycin and CTLA4Ig (abat-
acept/belatacept) (42,43)—are already clinically available.
Anti-CD40L, alas, is not and probably will not be any time
soon. However, anti-CD40 mAbs have been used with suc-
cess in chimerism and tolerance models (44,45) and they,
or other alternatives, might eventually be substituted for
anti-CD40L (46).
Treg therapy on its own seems most potent if hosts are
lymphopenic (47) or if Tregs are designed to express a spe-
cific TCR (16,17,29). In contrast, in this study we used poly-
clonal Tregs from wild-type mice, and fully allogeneic recip-
ients with an unperturbed T-cell repertoire. The remarkable
effectiveness of Tregs in this model is conceivably facili-
tated by the short time span during which their action is re-
quired to induce BM engraftment. Once BM has engrafted,
chimerism presumably contributes to maintenance of tol-
erance. Notably, all Treg populations tested—FoxP3-Tregs,
nTregs and iTregs—achieved the same outcome, suggest-
ing that this is a robust and reliable method for establishing
mixed chimerism without cytoreduction. Pending further
in-depth analysis into the three Treg subsets, it cannot
be ruled out at present, however, that the different Treg
populations achieve the same outcome through different
mechanisms.
Up to now, it has been considered necessary to trans-
plant clinically unobtainable high doses of allogeneic BM
to achieve engraftment in recipients not receiving cytore-
ductive treatment (4,14,48). Our results suggest that en-
graftment of moderate doses of allogeneic BM is feasi-
ble if the immunological host-versus-graft barrier is suf-
ficiently overcome. Treg therapy is uniquely potent in
this respect, as previous attempts have failed to reach
this goal through other interventions (49,50). Recently,
chimerism was induced with the help of Tregs, how-
ever, 5 Gy total body irradiation was required (11). Such
a sublethal dose of recipient irradiation is unacceptably
toxic for organ transplant patients as it leads—among
other side effects—to profound leukopenia and thus a
substantial risk of life-threatening infections. Remarkably,
a comparable magnitude of chimerism was achieved
in our present studies with 2 × 107 BM cells trans-
planted together with Tregs and rapamycin (plus costim-
ulation blockade) as had previously been obtained with
ten times as many BM cells (2 × 108 BM cells) trans-
planted with costimulation blockade alone (4,14). Like-
wise, levels of T-cell chimerism—albeit low—were similar
to what had been observed with 2 × 108 BM cells without
Tregs (4).
The transferred Tregs have a limited life-span (as indi-
cated by results from experiments with FoxP3-Tregs co-
expressing GFP) but nevertheless FoxP3+ regulatory cells
infiltrate tolerated donor skin. Accumulation of mast cells
in skin grafts also implies a role for regulatory mechanisms
in the maintenance of tolerance. In Treg-treated chimeras,
peripheral and central clonal deletion was evident but in-
complete late after BMT, providing evidence that tolerance
is maintained through a combination of deletional and reg-
ulatory mechanisms. Moreover, deletion progressed more
slowly over time than in mixed chimeras of previous stud-
ies induced with nonmyeloablative conditioning (3). Early
after BMT (∼2 weeks), when donor-hyporesponsiveness
is evident in MLRs and donor skin is already accepted (un-
published data), no deletion of donor-reactive T cells is yet
detectable in thymus and spleen. This is consistent with
the hypothesis that the relative contribution of nondele-
tional mechanisms inversely correlates with chimerism lev-
els (38) and previously published data showing that regu-
lation has a more prominent role in the early induction
phase after nonmyeloablative BMT (36). Taken together,
our results suggest that transferred Tregs induce BM en-
graftment with unique potency in recipients with intact
hematopoietic and immune systems. Chimerism having
been established through Treg therapy, tolerance is sub-
sequently maintained by both clonal deletion and nondele-
tional mechanisms apparently not requiring persistence of
the transferred Tregs.
Translation of the powerful tolerogenic effects of mixed
chimerism into widespread clinical use has so far been
prevented by the risks inherent in the necessary cytotoxic
recipient conditioning. Outlined in these studies is an ap-
proach that achieves mixed chimerism and tolerance with-
out these risks.
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